Applications of Sarpogrelate Hydrochloride in Industrial Manufacturing

Sarpogrelate Hydrochloride is an active pharmaceutical ingredient, primarily used in the synthesis of cardiovascular medications targeting platelet aggregation and vascular complications. As a direct manufacturer, we support multiple downstream sectors with high-quality, GMP-compliant material, strictly following regulatory and industrial requirements for the development and large-scale production of finished pharmaceuticals.

1. Cardiovascular Prescription Tablet Production

Pharmaceutical companies use Sarpogrelate Hydrochloride as the main active ingredient in the formulation of prescription tablets for antiplatelet therapy. Production environments demand cleanroom conditions, validated equipment, and precise blending to guarantee the stability, purity, and conforming dissolution profiles required by regulatory filings. The API integrates during the wet granulation or direct compression stage, followed by coating and strict batch release testing in certified laboratories.

Industry compliance standards

• Current Good Manufacturing Practice (cGMP) as per 21 CFR Parts 210 and 211 (FDA)
• ICH Q7 Guideline for Active Pharmaceutical Ingredients
• Japanese Pharmacopoeia (JP)
• European Pharmacopoeia (Ph.Eur.) for finished dosage forms

Typical usage ratio

• 50–100 mg per tablet, adjusted based on final therapeutic strength and target market specifications

Downstream process integration

• Added during granulation or direct blending as the principal API after initial excipient weighing; subject to in-process identification and homogeneity testing

Final product types

• 25 mg/50 mg/100 mg antiplatelet oral tablets
• Blister-packed finished pharmaceuticals for hospital and retail pharmacy channels

2. Injectable Formulation Manufacturing

Hospital-oriented manufacturers incorporate the raw material into sterile injectable formulations for acute vascular interventions. Production requires sterile filtration, aseptic filling, and lyophilization processes under internationally recognized pharmaceutical quality systems. Material input is tightly controlled and traceable, with full characterization and pyrogen testing required before bulk filling into ampoules or vials.

Industry compliance standards

• EU GMP for Sterile Medicinal Products (Annex 1)
• USP Chapter <797> for compounding sterile preparations
• Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP Guide
• Pharmacopoeia Monographs for Parenteral Products (JP, Ph.Eur., USP)

Typical usage ratio

• Concentration adjusted between 2–10 mg/mL in the injectable solution, based on single-dose and hospital requirement studies

Downstream process integration

• Dissolved and filtered before aseptic compounding; incorporated during the solution preparation stage prior to sterile filtration and filling

Final product types

• 2 mL/5 mL injectable vials or ampoules
• Ready-to-use hospital injectable kits for cardiovascular care units

3. Fixed-Dose Combination Drugs Development

Formulators in the cardiovascular therapeutic sector develop combination drugs by co-formulating Sarpogrelate Hydrochloride with statins or antihypertensive agents for multi-target patient populations. This involves compatibility testing, process validation, and stability studies under accelerated and real-time conditions. Regulatory submissions require full analytical documentation and continuous impurity profiling throughout production.

Industry compliance standards

• ICH Q8 (Pharmaceutical Development)
• National Medical Products Administration (NMPA) guidelines for combo products
• Relevant pharmacopoeial monographs (JP/Ph.Eur.)
• WHO GMP and bioequivalence reference standards

Typical usage ratio

• 10–100 mg Sarpogrelate per unit dose, balanced according to the second API and approved formulations

Downstream process integration

• Introduced during the primary blending stage; processed together with other APIs before tablet or capsule formation; in-line monitoring with validated HPLC or UPLC methods

Final product types

• Multi-ingredient oral tablets and capsules
• Combination therapies distributed for chronic cardiovascular management

4. Active Pharmaceutical Ingredient (API) Contract Manufacturing

API contract manufacturers source Sarpogrelate Hydrochloride as a starting material for further purification, reprocessing, or micronization according to client protocols. This process often requires polymorph screening, custom particle size distribution control, and compliance with project-specific impurity limits. Material batches receive full certificate of analysis with authenticated traceability per contract terms.

Industry compliance standards

• ICH Q3A/B (Impurities)
• GMP for APIs (ICH Q7)
• ISO 9001:2015 Quality Management for Custom Synthesis
• Pharmacopeial specification agreements as per client's market requirements (JP, US, EU)

Typical usage ratio

• Bulk input depends on target batch size; typically 10–500 kg per campaign, subject to downstream contract specifications and scale-up requirements

Downstream process integration

• Transferred from controlled storage to synthesis or purification reactors; micronization and validation sampling performed before packaging for shipment

Final product types

• Purified API lots with customized particle characteristics
• Microcrystalline Sarpogrelate for secondary pharmaceutical manufacturing and global export

5. Analytical Reference Substance Supply

Specialized laboratories and pharmaceutical quality control centers utilize high-purity Sarpogrelate Hydrochloride as reference material for method development, validation, and batch release testing. These applications require certified reference lots with comprehensive characterization and documented stability profiles. Manufacturing must ensure ultra-high purity and strict adherence to reference standard preparation guidelines, responding to audit and re-analysis requirements.

Industry compliance standards

• ISO/IEC 17025 for Analytical Laboratories
• USP Reference Standard Certification SOPs
• Pharmacopoeial standards (JP, USP, Ph.Eur.) for analytical substances
• ICH Q2 (Analytical Validation) requirements

Typical usage ratio

• Supplied in 10 mg–1 g vials; analytical use determines quantity per laboratory protocol

Downstream process integration

• Packed in inert atmosphere containers; entered into laboratory document management at QC departments; consumed in HPLC calibration, identification, and quantification

Final product types

• Chemical reference standards for regulatory submissions
• Internal QC reference samples for pharmaceutical release testing